Microbot Medical receives first Japanese patent for LIBERTY System; also patents in US, China, Israel

Microbot Medical Inc.

Japanese Patent Office granted first Japan patent covering core LIBERTY System technology for compact robotic surgical tool.
Company also received patents in the US, China, and Israel over the past 90 days, broadening global IP portfolio.
FDA marketing clearance for LIBERTY System announced on Sept 8, 2025; commercial launch targeting ~2.5M annual US peripheral procedures.
Management evaluating global markets that accept FDA clearance, with Japan seen as strategically important.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-25-016484
form_type: 8-K
ticker: MBOT
cik: 0000883975
company_name: Microbot Medical Inc.
filed_at: 2025-10-01T23:59:59+00:00
discovered_at: 2026-05-14T18:02:42.468956+00:00
generated_at: 2026-05-17T05:11:16.345230+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-25-016484
json_url: https://secwatch.observer/filing/0001493152-25-016484.json
markdown_url: https://secwatch.observer/filing/0001493152-25-016484.md
text_url: https://secwatch.observer/filing/0001493152-25-016484.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/883975/000149315225016484/0001493152-25-016484-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/883975/000149315225016484/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-25-016484

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.